Oral Immunostimulant Market size is expected to reach USD 33.6 Billion by the end of 2036, growing at a CAGR of 7.5% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of the oral immunostimulant was USD 23 Billion, which is attributed to the rising cases of chronic diseases like cancer, and cardiovascular diseases which weaken the immune system. According to a recent report, there were almost 17.8 million deaths in 2019 due to cardiovascular diseases worldwide. Furthermore, the role of oral immunostimulants is crucial in bolstering the immune system which leads to stimulating the market.
In addition, there is a growing demand for oral immunostimulants globally as patients seek comfortable treatment options over other forms of treatment. Oral Immunostimulant is a convenient option for patients as it can be taken in pill or liquid form. Moreover, oral immunostimulant reduces the possible infections and other complications among patients which further boosts the growth of the market.
Growth Drivers
Challenges
Base Year |
2023 |
Forecast Year |
2024-2036 |
CAGR |
~ 7.5% |
Base Year Market Size (2023) |
~ USD 23 Billion |
Forecast Year Market Size (2036) |
~ USD 33.6 Billion |
Regional Scope |
|
By Type (Interleukins, Glucan, Lipopolysaccharides, Levamisole, Isoprinosine)
The interleukins type segment is predicted to account for 51% share of the global oral immunostimulant market by 2036. The segment growth can be attributed to the factor that interleukins are involved in the modulation and responses of immune responses. Oral immunostimulants that leverage the specific interleukins can influence the immune system’s activity, helping to enhance the body’s defense mechanisms against infections or diseases. In addition, the ongoing research into the roles of interleukins in immune functions fuels innovation in the oral immunostimulants market. Companies are exploring ways to harness the potential of interleukins for developing next-generation oral immunostimulant products that stimulate segment growth.
By Application (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies)
The hospital pharma segment is predicted to account for 54% share of the global oral immunostimulant market by 2036. The segment growth can be attributed to the factor that hospitals play a crucial role in the treatment of acute illness and infectious diseases. According to a recent report, a total of 66 infectious diseases were reported in 2021. Oral immunostimulants are often prescribed in these settings to support patient immune responses during their stay, aiding in faster recovery. In addition, the strong relationship and partnership between healthcare providers and pharmaceutical companies play an important role in the adoption and promotion of oral immunostimulants.
Our in-depth analysis of the global market includes the following segments:
By Type |
|
By Application |
|
North American Market Forecast
The oral immunostimulant market in the North American region, is anticipated to hold the largest share of about 44% by the end of 2036. The regional growth is attributed to the factor that well-established healthcare infrastructure and a high prevalence of chronic diseases. In addition, the COVID-19 pandemic has highlighted the importance of immune health, leading to a surge in interest and investment in immunostimulant therapies. According to a recent report, there were at least 1,064,000 reported deaths caused by a novel coronavirus in North America in 2022. As a result, oral immunostimulants have gained attention as a potential tool for enhancing the body’s natural defenses against infections, including respiratory illnesses like COVID-19 which stimulate the market in the region.
European Market Analysis
The Europe market is estimated to be the second largest, registering a share of about 30% by the end of 2036. The market’s expansion can be attributed to Europe’s commitment to healthcare innovation and huge investment in healthcare research created a favorable environment for the oral immunostimulant market. In addition, the integration of digital health tools like mobile health applications helps in patient monitoring and provides real-time data. This digital integration improves overall patient management and contributes to the effectiveness of oral immunostimulant therapies. Moreover, healthcare innovation in the region acts as a catalyst for the growth of the oral immunostimulant market by pushing the boundaries of scientific knowledge improving treatment outcomes, and addressing immune-related disorders and infectious diseases.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?